Boström A, Boström J, Hartmann W, Pietsch T, Feuss M, von Lehe M, Simon M
University Hospital of Bonn Medical Center, Department of Neurosurgery, Germany.
Cent Eur Neurosurg. 2011 Aug;72(3):127-32. doi: 10.1055/s-0031-1273745. Epub 2011 May 31.
To evaluate the treatment outcomes of patients with intracranial ependymomas.
Between 1988-2007, 27 consecutive patients, with 9 patients (33%) aged under 16 years, were treated at our institution for an intracranial ependymoma. Pertinent clinical data were retrieved from the patients' charts. The histopathological findings in 25 cases were reviewed using the 2007 World Health Organization (WHO) classification system. Median follow-up was 84 months.
Infratentorial tumors were diagnosed in 22, and supratentorial tumors in 5 patients. Histopathological findings were ependymoma WHO grade II (E II) in 14 patients, and anaplastic ependymoma WHO grade III (AE III) in 13 patients. A complete tumor resection was achieved with the first operation in 20 cases (74%). Primary adjuvant therapy consisted of chemotherapy alone in a 17-month-old child with an incompletely resected posterior fossa AE III, radiation therapy alone in 4 cases, and combined radiation therapy and chemotherapy in 7 cases. Tumor recurrence was seen in 10 cases (37%), including 5 patients with an E II and 5 patients with an AE III. The 5-year progression-free survival (PFS) was 74% and 67% for E II and AE III, respectively. The 5-year PFS was 80% following a complete resection, and 56% in patients with a residual tumor.
Surgery alone, as the primary treatment, achieves a good outcome in most patients with E II. Good results can be achieved with surgery and adjuvant local radiotherapy in patients with AE III.
评估颅内室管膜瘤患者的治疗效果。
1988年至2007年间,我院连续收治了27例颅内室管膜瘤患者,其中9例(33%)年龄在16岁以下。从患者病历中检索相关临床资料。使用2007年世界卫生组织(WHO)分类系统对25例患者的组织病理学检查结果进行回顾。中位随访时间为84个月。
幕下肿瘤22例,幕上肿瘤5例。组织病理学检查结果显示,14例为WHO二级室管膜瘤(E II),13例为间变性WHO三级室管膜瘤(AE III)。20例(74%)患者首次手术即实现了肿瘤全切除。主要辅助治疗包括:1例17个月大的后颅窝AE III切除不完全的患儿仅接受化疗;4例仅接受放射治疗;7例接受放化疗联合治疗。10例(37%)患者出现肿瘤复发,其中E II患者5例,AE III患者5例。E II和AE III患者的5年无进展生存率分别为74%和67%。肿瘤全切除后的5年无进展生存率为80%,有残留肿瘤患者的5年无进展生存率为56%。
对于大多数E II患者,单纯手术作为主要治疗方法可取得良好效果。对于AE III患者,手术联合辅助局部放疗可取得较好疗效。